Table 3.
Factors associated with pregnancy planning.
| Planned pregnancy(n = 46) | Unplanned pregnancy(n = 36) | p-value | ||
|---|---|---|---|---|
| Age at last pregnancy years, Mean (SD) | 32.98 (4.62) | 34.30 (5.93) | 0.37 | |
| Motherhood before MS diagnosis, n (%) | 18 (34.6) | 10 (33.3) | 0.91 | |
| Year of the last pregnancy, median (IQR) | 2014.50 (7) | 2014 (8.5) | 0.70 | |
| Information from health workers regarding family planning in the last pregnancy | Yes | 39 (84.8) | 22 (61.1) | 0.02 |
| No | 7 (15.2) | 14 (38.9) | ||
| Treatment before the last pregnancya | Injectable drugs | 31 (67.4) | 12 (46.2) | 0.08 |
| Other treatmentb | 15 (32.6) | 14 (53.8) | ||
| Pregnancy planning strategy used n (%) | Stopped DMT and CM at the same timea | 13 (28.2) | – | NA |
| Stopped DMT and continued CM for a timec | 10 (21.8) | – | NA | |
| Stopped DMT after positive pregnancy testd | 23 (50) | – | NA | |
Note: Patients that became pregnant after being diagnosed with Multiple Sclerosis: Information related to the last pregnancy.
SD: standard deviation; Injectable drugs: Interferon or glatiramer acetate, DMT: Drug modified treatment. CM: contraception method.
a7 Injectable drugs, 3 natalizumab and 3 dimethyl fumarate.
bOther treatment: Fingolimod, dimethyl fumarate, cladribine; natalizumab, ocrelizumab.
c1 ocrelizumab, 2 fingolimod, 2 cladribine.
d19 Injectable drugs, 1 natalizumab, 2 dimethyl fumarate.Bold numbers mark the degree of significance.